<DOC>
	<DOCNO>NCT02258854</DOCNO>
	<brief_summary>The purpose study provide continue dose gevokizumab order obtain assess long-term gevokizumab safety data .</brief_summary>
	<brief_title>An Open-label , Rollover Study Providing Continued Dosing Gevokizumab Order Assess Long-term Gevokizumab Safety Data</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Completed either X052130/CL378989005 X052131/CL378989006 study 's mask D392 OL224 completion day visit control ocular inflammation receive study drug Part 2 study X052133 Discontinued previous study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Non-infectious Uveitis</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Posterior Uveitis</keyword>
	<keyword>Panuveitis</keyword>
	<keyword>Beh√ßet 's disease uveitis</keyword>
</DOC>